Company intelligence / Profile preview

Iken Tissue Therapeutics

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Iken Tissue Therapeutics (later renamed Theregen) was a biotechnology company focused on developing tissue-engineered therapies for cardiovascular diseases. Its lead product, Anginera, was a human fibroblast-based epicardial patch designed to induce the formation of mature blood vessels in the human myocardium. The technology aimed to address ischemia and promote arteriogenesis in patients with heart failure or damaged cardiac tissue. The company was based in San Francisco and eventually ceased operations after reaching early-stage clinical testing.

Therapeutic areas: Cardiovascular
Modalities: Cell therapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Iken Tissue Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iken Tissue Therapeutics.

Explore the full profile